Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ORCL$119.50-11.17(-8.55%)UPDATE 6-Oracle taps investors for $20 billion to finance AI expansion10:58:17 PM ETSKHY$148.53-0.68(-0.46%)Samsung and SK Hynix stocks plunge as a $20 billion AI shock rattles markets10:39:42 PM ETC$123.30+0.46(+0.38%)Japanese, Korean, Taiwanese firms' US investment set to keep climbing: Citi10:38:12 PM ETKO$95.96+1.88(+2.00%)Coca-Cola Is Exercising its Pricing Power as Inflation Persists10:35:02 PM ETGOOG$279.21+0.99(+0.36%)Google takes Dreambeans to India in bid to bring AI-generated personal stories to the masses10:30:00 PM ETORCL$119.50-11.17(-8.55%)BRIEF-Oracle Prices $20 Billion Of Common Stock And Senior Notes10:16:41 PM ETORCL$119.50-11.17(-8.55%)Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes10:10:08 PM ETPLTR$173.00-11.11(-6.03%)Palantir Technologies Inc. (PLTR) Q3 2026 Earnings Call Transcript10:08:30 PM ETIUSG$181.79-1.75(-0.95%)IUSG: Hyperscaler Sell-Off Is Overblown - Buy The Dip9:19:55 PM ETAAPL$328.81-15.82(-4.59%)Apple Forecasts Slower Services Growth as AI Costs Rise9:09:51 PM ETCRDO$140.88-10.11(-6.70%)Credo vs. Sandisk: Which Stock Is the Better Buy for 2027?9:00:02 PM ETAAPL$328.81-15.82(-4.59%)Apple may try to increase revenue by doing8:49:52 PM ETCVX$228.21-7.75(-3.29%)Chevron & Exxon Mobil Stocks Retreat From 52-Week Highs: Buy the Dip?8:21:06 PM ETAAPL$328.81-15.82(-4.59%)Apple Q4 Earnings Call Highlights8:14:45 PM ETPLTR$173.00-11.11(-6.03%)What Palantir Technologies (PLTR) Said on Its Q3 Earnings Call8:14:22 PM ETACN$261.99+3.75(+1.45%)Top 25 Attractive Dividend Stocks For November 20268:10:22 PM ETPLTR$173.00-11.11(-6.03%)Here's why Palantir's stock is down despite a ‘bombastic' quarter7:59:00 PM ETAAPL$328.81-15.82(-4.59%)Apple's iPhone business is booming. Here's why the stock is falling anyway.7:52:00 PM ETAMZN$246.44+5.28(+2.20%)Amazon's Report Passed Both Tests I Set for It. I'd Buy More of the Stock Now.7:47:01 PM ETAAPL$328.81-15.82(-4.59%)Apple Inc. (AAPL) Q4 2026 Earnings Call Transcript7:38:25 PM ETDIS$113.50+2.17(+1.96%)Disney eyes thousands of layoffs, managers asked to cut 20% in costs, Bloomberg News reports7:36:37 PM ETAMD$472.00-37.96(-7.52%)AI Earnings: 3 Reports to Watch This Week7:31:11 PM ETAAPL$328.81-15.82(-4.59%)Big Quarterly Beats After the Close: AAPL, PLTR, LSCC, ROKU7:21:04 PM ETGEV$861.08+3.21(+0.37%)Why GE Vernova Stock Crept Higher on Monday7:16:10 PM ET

JAZZ · NASDAQ

Jazz Pharmaceuticals plc

$214.43 +8.15 (+3.92%)

Company overview

Jazz Pharmaceuticals plc is a biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates focused on neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients; Sunosi for excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; Erwinaze for acute lymphoblastic leukemia; Defitelio for hepatic veno-occlusive disease; Vyxeos liposome for newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for metastatic small cell lung cancer.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$13.9B
Employees
2,800
Headquarters
Dublin
Website
jazzpharma.com
CEO
Renee D. Gala
Listed
June 1, 2007
P/E
523.00
Dividend yield
0.00%

Company financials

Revenue
$4.4B
Gross profit
$3.7B
Operating income
$494M
EBITDA
$395M
Net income
$29.5M
EPS
$0.41
Total assets
$11.9B
Total debt
$5.4B
Gross margin
84.12%
Net margin
0.66%
Earnings yield
0.19%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

198.40216.04233.69251.34268.99
JAZZ 1D NASDAQ O215.84H218.36L213.99C214.46-1.52 (-0.70%)Vol695.49K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript Seeking Alpha
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals Q3 Earnings Call Highlights MarketBeat
JAZZJazz Pharmaceuticals plc Stock news Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks Investment Research
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates Zacks Investment Research
JAZZJazz Pharmaceuticals plc Stock news Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted Reuters
JAZZJazz Pharmaceuticals plc Press release Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26). "Our third-quarter performance... PR Newswire
JAZZJazz Pharmaceuticals plc Stock news BRIEF-Jazz Pharmaceuticals To Highlight Neuro-Oncology Clinical Research At Sno 2026 Reuters
JAZZJazz Pharmaceuticals plc Press release Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at ... PR Newswire
JAZZJazz Pharmaceuticals plc Stock news Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine The Motley Fool
JAZZJazz Pharmaceuticals plc Stock news Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for Zacks Investment Research
JAZZJazz Pharmaceuticals plc Press release Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall surviva. PR Newswire
JAZZJazz Pharmaceuticals plc Press release Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after... PR Newswire
JAZZJazz Pharmaceuticals plc Stock news Is JAZZ Stock Still a Smart Way to Play Medical Cannabis? Zacks Investment Research
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story Seeking Alpha
JAZZJazz Pharmaceuticals plc Stock news Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? The Motley Fool
JAZZJazz Pharmaceuticals plc Stock news Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock Zacks Investment Research
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B MarketBeat
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands MarketBeat
JAZZJazz Pharmaceuticals plc Stock news Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? The Motley Fool
JAZZJazz Pharmaceuticals plc Stock news Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Seeking Alpha
See more
FAQ

Questions about Jazz Pharmaceuticals plc

What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc is a biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates focused on neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients; Sunosi for excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; Erwinaze for acute lymphoblastic leukemia; Defitelio for hepatic veno-occlusive disease; Vyxeos liposome for newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for metastatic small cell lung cancer.
What is JAZZ's market cap?
Jazz Pharmaceuticals plc (JAZZ) is a listed stock with a live quote. The latest market cap on this page is $13.9B.
Where is Jazz Pharmaceuticals plc headquartered?
Jazz Pharmaceuticals plc is headquartered in Dublin.
How do I get JAZZ news from the API?
Call GET /v1/news?tickers=JAZZ. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does JAZZ news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for JAZZ, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the JAZZ price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs